| Patent Number |
Title Of Patent |
Date Issued |
| 5981170 |
Peptides, artificial antigens and immunoassay kits |
November 9, 1999 |
| An artificial peptide having an amino acid sequence which corresponds to a naturally occurring amino acid sequence of a HIV comprising an epitope and which further has two cysteine residues located on each side of said epitope, and further having a sulphur bridge between said two cystein |
| 5726287 |
Synthesis of cyclic peptides |
March 10, 1998 |
| A process for preparing and purifying cyclic peptides having disulfide moieties in a single processing operation which simplifies synthesis and reduces production costs, yet produces high, quality yield. Higher yields are obtained by isolating the desired cyclic compound through direct i |
| 5674850 |
High purity desmopressin produced in large single batches |
October 7, 1997 |
| A process for the manufacture of high purity desmopressin produced in single batches of substantial size and a method of treating diabetes insipidus with the high purity desmopressin produced therefrom. |
| 5629146 |
Method for detection of human papillomavirus (HPV) for diagnostic purposes |
May 13, 1997 |
| Method for detection of infection with human papillomavirus (HPV) for diagnostic purposes, particularly for diagnosing carcinoma, or pre-stages thereof, or the risk of development of carcinoma. The detection is effected on a body fluid, particularly on a secretion from cervix uteri, |
| 5596078 |
Synthesis of cyclic peptides |
January 21, 1997 |
| A process for preparing and purifying cyclic peptides having disulfide moieties in a single processing operation which simplifies synthesis and reduces production costs, yet produces high, quality yield. Higher yields are obtained by isolating the desired cyclic compound through direct i |
| 5500413 |
Process for manufacture of 1-deamino-8-D-arginine vasopressin |
March 19, 1996 |
| A process for the manufacture of 1-deamino-8-D-arginine vasopressin (DDAVP) comprising, condensing a preparation of Mpa(R.sup.1)-Tyr-Phe-Gln-Asn-Cys(R.sup.2)-Pro-OH (SEQ ID NO: 1), where R.sup.1 and R.sup.2 are sulfhydryl-protecting groups, with the dipeptide (R.sup.3)-D-Arg(HCl)-Gly |
| 5498598 |
Composition for nasal administration of desmopressin |
March 12, 1996 |
| An aqueous composition for spray nasal administration of a synthetic analog of vasopressin (desmopressin; actate containing between 2.5 and 7.5 .mu.g per 100 .mu.l. The composition may additionally contain an osmotic-pressure controlling agent, such as sodium chloride, a preservative |
| 5482931 |
Stabilized pharmaceutical peptide compositions |
January 9, 1996 |
| Disclosed is a stabilized aqueous composition for administration to a patient comprising a biologically active peptide, a buffer, a quaternary amine-type preservative or disinfectant, and an osmotic pressure-controlling agent, which composition can be stored and used at room temperat |
| 5459236 |
Vasoactive vasotocin derivatives |
October 17, 1995 |
| The present invention relates to new vasotocin derivatives with prolonged activity compared to previous vasotocin derivatives. In particular, the vasotocin derivatives of the present invention are of the formula (I) ##STR1## wherein Hmp is a 2-hydroxy-3-mercaptopropionic acid residue |
| 4504469 |
Vasotocin derivatives |
March 12, 1985 |
| Novel vasotocin derivatives having an inhibitory effect on uterine contractions, pharmaceutical compositions containing these derivatives, and the use thereof in the therapeutical treatment of excessive muscle contractions in the uterus and described. The derivatives differ from vaso |
| 4402942 |
Oxytocin derivatives |
September 6, 1983 |
| New oxytocin derivatives having an inhibitory effect on uterine contractions, pharmaceutical compositions containing the oxytocin derivatives, and use of the derivatives in the production of medicines are described. The derivatives are 1-deamino-(2-O-alkyltyrosine)-oxytocin of the fo |
| 4148787 |
Antidiuretically effective polypeptide and a process for preparing the same |
April 10, 1979 |
| Antidiuretically effective vasopressin derivates of the formula ##STR1## in which Mep is a 2-mercaptopropionyl residue (--S--CH.sub.2 CH.sub.2 CO--), and A and B are glutamine (Gln) or asparagine (Asn) and A is Gln only when B is Gln and D-arginine is in position 8.A method for prepa |
